NF-kappaB inhibition restores sensitivity to Fas-mediated apoptosis in lymphoma cell lines

Area of Science:

• Immunology
• Molecular Biology
• Cancer Research

Background:

• The Fas apoptosis pathway is crucial for eliminating tumor cells, but its failure leads to resistance against chemotherapy and immunotherapy.
• Constitutively activated nuclear factor kappa B (NF-kappaB) is frequently observed in tumors and implicated in apoptosis resistance.

Purpose of the Study:

• To investigate the role of NF-kappaB in Fas-mediated apoptosis resistance.
• To explore the potential of NF-kappaB inhibition as a strategy to overcome Fas-resistance in T-lymphoma cells.

Main Methods:

• Utilized Fas-sensitive (HuT78) and Fas-resistant (HuT78B1, HuT78G9) human T-lymphoma cell lines, all expressing high levels of activated NF-kappaB.
• Treated cells with NF-kappaB inhibitors (PDTC, MG132, SN50) and assessed the impact on CH11-induced apoptosis.
• Investigated the involvement of caspases and Fas-blocking antibodies in the observed synergistic effects.

Main Results:

• NF-kappaB inhibition, particularly with PDTC, MG132, or SN50, significantly enhanced CH11-induced apoptosis in HuT78 and HuT78G9 cells.
• MG132 demonstrated a similar potentiating effect in the HuT78B1 cell line.
• The synergistic effect of NF-kappaB inhibitors was dependent on caspase activation, as indicated by inhibition with a pancaspase inhibitor (Z-VAD-FMK) and an anti-Fas-blocking antibody (ZB4).

Conclusions:

• NF-kappaB signaling plays a critical role in mediating resistance to Fas-induced apoptosis.
• Inhibiting NF-kappaB can restore the sensitivity of Fas-resistant, NF-kappaB-overexpressing tumors to apoptosis.
• Targeting NF-kappaB represents a promising therapeutic strategy to enhance the efficacy of cancer treatments that rely on the Fas pathway.